Compare Enzyme (MLN) vs Symbiosis (SIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enzyme vs Symbiosis — how do they compare? Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume), while Symbiosis trades at Rp293.08 (market cap Rp34,08M, Rp2,71M 24h volume). The key difference: Enzyme is far larger — about 3.9× Symbiosis's market cap, and Symbiosis's supply is capped (97M / 99,5M SIS (98%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Enzyme for 29 Days and Symbiosis for 13 Days on average.
| MLN | SIS | |
|---|---|---|
Market Cap | Rp134,13M | Rp34,08M |
Volume (24h) | Rp104,56M | Rp2,71M |
Circulating Supply | 3,3M MLN | 97M / 99,5M SIS (98%) |
Typical Hold Time | 29 Days | 13 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
Symbiosis (SIS) shows limited market activity with a modest market cap of Rp34.08M and high circulating supply utilization at 98%. The token exhibits a short average hold time of 13 days, suggesting active trading but potentially weak long-term holder confidence. No recent protocol updates or significant ecosystem developments have been recorded, indicating stagnant project momentum.
Overall outlook remains cautious due to low market cap and limited fundamental catalysts. Key opportunities include potential ecosystem growth if development resumes, while major risks involve low liquidity, high volatility typical of small-cap tokens, and regulatory uncertainty in the crypto space.
About Enzyme
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →About Symbiosis
Symbiosis is a platform for cross-chain swaps that eliminates the need for multiple transactions. It aggregates liquidity from various Automated Market Makers (AMMs) and Decentralized Exchanges (DEXs) across EVM and non-EVM chains. The platform uses a decentralized Relayers Network, consisting of relayer nodes that verify and transfer information across blockchains. This network ensures secure data transfer and enhances security against central points of failure. Relayer nodes must stake SIS tokens to participate in the consensus and process swaps.
Read more on SIS →
